Candida glabrata is a prominent opportunistic fungal pathogen of humans. The increasing
incidence of C. glabrata infections is attributed to both innate and acquired resistance to …

Candida glabrata emerged in the last decade as a common cause of mucosal and invasive
fungal infection, in large part due to its intrinsic or acquired resistance to azole antifungals …

The fungal pathogen Candida glabrata is an emerging cause of candidiasis in part owing to
its robust ability to acquire tolerance to the major clinical antifungal drug fluconazole. Similar …

Candida glabrata, a yeast with intrinsically low susceptibility to azoles, frequently develops
increased azole resistance during prolonged treatment. Transposon mutagenesis revealed …

The high prevalence of fluconazole resistance among clinical isolates of Candida glabrata
has greatly hampered the utility of fluconazole for the treatment of invasive candidiasis …

Fluconazole is one of the most commonly used antifungals today. A result of this has been
the inevitable selection of fluconazole-resistant organisms. This is an especially acute …

Azole drugs are the most frequently used antifungal agents. The pathogenic yeast Candida
glabrata acquires resistance to azole drugs via single amino acid substitution mutations …

The primary route for development of azole resistance in the fungal pathogen Candida
glabrata is acquisition of a point mutation in the PDR1 gene. This locus encodes a …

Candida glabrata has emerged as a common cause of fungal infection. This yeast has
intrinsically low susceptibility to azole antifungals such as fluconazole, and mutation to frank …

The opportunistic yeast pathogen Candida glabrata is recognized for its ability to acquire
resistance during prolonged treatment with azole antifungals (JE Bennett, K. Izumikawa, and …